Ellomay Capital — Company guidance for FY18 confirmed at Q1

Ellomay Capital — Company guidance for FY18 confirmed at Q1

Over 2017, Ellomay made large investments in new projects and in acquisitions, which we expect to drive significant revenue and profit growth in 2018. Results for Q1 (normally weak due to seasonality) showed a 20% y-o-y growth in revenues and were in line with management expectations for FY18. We expect the following quarters to also show a pick-up in earnings. Looking beyond 2018, Ellomay has announced significant progress on Talasol, a large Spanish solar PV plant, which could reach financial close before the 2018 year-end. Our valuation of $11.0 per share implies c 28% potential upside.

Analyst avatar placeholder

Written by

Ellomay Capital

Company guidance for FY18 confirmed at Q1

Q1 results update

Alternative energy

10 July 2018

Price*

US$8.60

Market cap

US$92m

*Priced at 4 July 2018.

€/US$1.16

Net debt (€m) at end Q118

80.5

Shares in issue

10.7m

Free float

31%

Code

ELLO

Primary exchange

NYSE

Secondary exchange

TASE

Share price performance

%

1m

3m

12m

Abs

6.0

7.6

(1.8)

Rel (local)

6.9

(6.6)

(12.1)

52-week high/low

US$10.6

US$7.7

Business description

Ellomay Capital is a renewable power and energy infrastructure owner, operator and developer. Its core asset portfolio includes solar PV plants in Italy (22.6MW), Spain (7.9MW) and Israel (9MW). Ellomay owns a stake in a gas-fired plant in Israel and is building biogas plants in the Netherlands.

Next events

H118 results

September 2018

Analysts

Dario Carradori

+44 (0)20 3077 5700

Graeme Moyse

+44 (0)20 3077 5700

Over 2017, Ellomay made large investments in new projects and in acquisitions, which we expect to drive significant revenue and profit growth in 2018. Results for Q1 (normally weak due to seasonality) showed a 20% y-o-y growth in revenues and were in line with management expectations for FY18. We expect the following quarters to also show a pick-up in earnings. Looking beyond 2018, Ellomay has announced significant progress on Talasol, a large Spanish solar PV plant, which could reach financial close before the 2018 year-end. Our valuation of $11.0 per share implies c 28% potential upside.

Year end

Revenue (€m)

PBT*
(€m)

EPS*
(€)

DPS
(€)

P/E
(x)

Yield
(%)

12/17

13.6

(6.3)

(0.57)

0.00

NA

N/A

12/18e

19.7

3.6

0.28

0.09

26.4

1.2

12/19e

20.5

4.5

0.34

0.11

21.8

1.5

12/20e

20.4

4.3

0.33

0.12

22.4

1.6

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Q1 revenues up 20% y-o-y and guidance confirmed

Q1 revenues were €3.0m, +20% y-o-y, driven mostly by new projects (Dutch biogas) and acquisition (Israel solar PV). EBITDA was €1.3m (vs €1.5m in Q117). Correcting for a €0.4m negative one-off impact, we calculate that EBITDA would have been up c 13% y-o-y. Ellomay reported a net loss of €0.4m (vs a loss of €1.7m in Q117), which we expect to turn into a FY net profit after two years of losses, thanks to the contribution of the (seasonally stronger) following quarters. We updated our estimates for results and to align the accounting treatment of Talmei Yosef project with the company’s. On an underlying basis we have reduced our FY18-20 net income forecasts by 7-9% post Q1. The company said that Q1 results were consistent with its previous forecasts for FY18 (€21.9m cash flow from the sale of electricity and gas, and total net cash flow from projects of €11.8m).

A pipeline of large projects

Ellomay has a pipeline of large projects, including the Manara Cliff pumped-storage project and the solar Spanish PV project, Talasol, on which it announced significant progress in June. In addition to these two projects, at the Q1 results Ellomay said it is promoting the expansion of its Dutch biogas projects and acting to add additional projects as well. Overall, we believe the outlook for structural renewable growth in Europe remains robust and the recently increased EU target for renewables provides a positive backdrop, despite the threat of rising interest rates and the risk of returns compression. While growth opportunities exist, we believe the main challenge for Ellomay will be financing new projects.

Valuation of $11.0/share implies 28% potential upside

Ellomay’s current share price implies an equity valuation broadly in line with book value, hence the market is discounting little ability to create value from existing and future development projects. We believe delivery of earnings growth from new projects would provide an opportunity to crystallise the upside potential. Our DCF-based value of US$11.0/sh (vs $11.4/sh previously) implies c 28% potential upside.

Q118 revenues up 20% y-o-y

On 21 June, Ellomay Capital reported Q1 results:

Revenues were €3.0m, up 20% y-o-y, mostly driven by new projects (waste-to-energy in the Netherlands) and acquisition (Talmei Yosef, a solar PV asset in Israel acquired in October 2017). The Talmei Yosef project contributed only €0.2m revenues rather than the total proceeds from the sale of electricity of €0.8m, due to accounting treatment IFRIC 12, service concession arrangements.

EBITDA was €1.3m (vs €1.5m in Q117). The first quarter is traditionally a weak one due to seasonality (radiation levels are low during the winter), which affects revenues and has a disproportionate impact on margins (as costs, which are equally split over the various quarters, increase as a result of new projects but are not compensated by a similar increase in revenues). In addition, EBITDA was affected by a €0.4m negative one-off impact (included in general and administrative expenses) due to a payment following a VAT assessment agreement in connection with previous years in Israel. Correcting for this negative one-off, we calculate that EBITDA would have been up c 13% y-o-y.

Net loss of €0.4m (vs a loss of €1.7m a year earlier) includes a net positive one-off impact of €0.3m due to lower financial expenses resulting from exchange rate differences (in addition to the €0.4m negative one-off impact included in EBITDA, mentioned above). As a result, we estimate a c €0.3m net loss on an underlying basis for Q118. We expect this loss to turn into a profit for the full year, thanks to the contribution from the (seasonally stronger) following quarters.

Net debt was €80.5m, broadly unchanged vs FY17 results, with cash flow from operations covering cash outflows from investments.

The company commented that Q1 results were consistent with its previous forecasts for FY18. Previously released guidance included an estimate of €21.9m cash flow from the sale of electricity and gas, and total net cash flow from projects (including an equity-accounted stake in gas plant Dorad) of €11.8m.

Ellomay’s project pipeline include large investments

Ellomay has a pipeline of large projects for future years, which are not included in our forecasts (as they have not reached financial close) and which we believe represent significant growth opportunities in the medium term. Beyond Talasol (a 300MW solar PV plant project in Talaván, Spain, with financial close potentially by year-end) and Manara Cliff (a 156MW Israeli pumped-storage plant project), in its latest results release, Ellomay Capital added that it could expand the capacity of its first two biogas projects (one of which is due to come on stream over the course of 2018) and that it could add similar new projects in the Netherlands. We understand that no investment decision has been made and we expect these projects to be advanced depending on the attractiveness of returns and on funding availability.

Exhibit 1: Key pipeline projects

Location

Asset

Expected commissioning

Expected capex

Generation

Expected revenue

Talaván, Spain

300MW solar PV in Spain

2020

€200-230m

545GWh
year

€20-25m/
year

Manara Cliff, Israel

156MW pumped-storage hydro plant

N/A

N/A

N/A

N/A

Biogas projects, Netherlands

Potential expansion of the existing projects and potential new projects

N/A

N/A

N/A

N/A

Source: Company data

Over the last few weeks, Ellomay has achieved significant progress on the Talasol project. In June the company announced that it had entered into an engineering, procurement & construction agreement for the project and that it is discussing the possibility of receiving financing from the European Investment Bank. The project (with total capex of €200-230m) is expected to have leverage of 60%. In addition, Ellomay announced that it had executed a financial power swap in respect of c 80% of the output of the plant (power purchase agreement).

Beyond these projects, we believe the company could evaluate several other growth projects in the future and that the outlook for new renewable projects remains strong, despite the prospect of increasing interest rates and the recent compression in returns of new projects.

After 18 months of negotiations, the European Council agreed in June to increase the target for the share of EU energy consumption from renewables to 32% from 27% (vs 17% in 2016), which should provide a positive backdrop for further renewable growth in Europe. For example, Italy (Italian assets generate around half of Ellomay’s 2018e revenues, on our estimates) would require a boost in total renewable investments to €87bn (from €70bn) in the period 2018-30 to reach the higher target, according to estimates by Osservatorio OIR (published in La Repubblica on 20 June 2018). This would require a huge step-up in investments, from €2.1bn in 2017 (source: Bloomberg New Energy Finance) to €6.7bn/year in the period 2018-30.

We believe a key constraint to Ellomay’s future growth projects is its ability to fund new investments. We forecast FY19 net debt/EBITDA of 4.8x with a reduction thereafter, thanks to cash flow generation (before any further projects). In November 2017 Standard & Poor’s (S&P) Maalot downgraded the rating of the company and its Series A and Series B Nonconvertible Debentures from ilA- with a “negative” outlook to ilBBB+ (which corresponds to B on an S&P’s global scale), although the outlook is now “stable”. The downgrade was justified on the basis of the level of estimated FFO to adjusted debt ratio (9-12% in forthcoming years). Maalot said Ellomay Capital’s level of liquidity was appropriate.

New projects point to FY18 growth

We believe the H1 results in September will provide better visibility on Ellomay’s growth prospects over the course of 2018, which we continue to see as an important year of growth delivery for the company. We now forecast FY18 revenues increasing by 44% y-o-y to €19.7m and EBITDA growing by 60% y-o-y to €12.0m (see forecasts revisions in Exhibit 2 below). In addition, we expect Ellomay to report positive net income (€2.5m) following net losses over the course of FY16 and FY17. This should allow Ellomay to declare a dividend from FY18 (we assume a c 33% payout ratio in line with company guidance). Beyond 2018, our estimates point to a stabilisation in revenue and EBITDA as our forecasts do not include further growth projects. New projects, such as Talasol, would provide significant upside to our estimates.

Forecasts update post Q1 results

We have updated our forecasts following Q1 results and aligned our modelling with Ellomay’s accounting treatment for Talmei Yosef (the recently acquired solar PV asset). While previously we included 100% of revenues for the project, we now include 25% (related to the operations of the asset) and 75% against financial assets, in line with the accounting treatment by the company (IFRIC 12 – service concessions). This has an impact on revenue and EBITDA, but no impact on cash flow. Overall we expect Ellomay to report a strong improvement in revenues and net income over the course of FY18, although our net income forecasts for FY18-20 reduce by 7-9% on an underlying basis, reflecting updated assumptions for project development costs, financial expenses, D&A and contribution from assets in Israel.

Exhibit 2: Forecasts revisions

€000s

2018e

2019e

2020e

EBITDA

New

11,958

12,719

12,628

Old

14,317

14,900

14,833

% change

-16%

-15%

-15%

EBIT

New

6,200

6,752

6,661

Old

8,259

8,634

8,566

% change

-25%

-22%

-22%

Net income adjusted for minorities

New

2,490

3,049

2,930

Old

2,724

3,281

3,198

% change

-9%

-7%

-8%

Source: Edison Investment Research

Valuation: $11.0/share implies 28% potential upside

We have made small changes to our valuation, mostly reflecting updated forecasts and FX assumptions. Our fair value is calculated with a DCF-based sum-of-the-parts valuation and is $11.0/share, (vs $11.4/share previously), which implies 28% potential valuation upside to the current share price.

We use an average WACC of c 5% and assume an asset life of 20 years for Italian and Israeli solar PV plants, 25 years for Spanish solar PV and 12 years for Dutch WTE plants. The valuation implies an EV of €170m and equity value of €101m.

The current share price implies that Ellomay trades broadly in line with book value (€76m at Q118), which shows that the market is discounting little ability for it to generate returns above the cost of capital. We believe growth delivery could drive a re-rating and see the H118 results as an important checkpoint.

In our view, the key risks that Ellomay faces are:

1.

regulatory: solar PV assets are heavily regulated and, as a result, the company faces the risk of regulatory changes;

2.

operational: weather conditions may drive higher or lower output than expected (eg 2016 was an unfavourable year for solar PV production) and higher/lower power prices in Italy and Spain could drive higher/lower profits for the company; and

3.

currency: for euro investors, we estimate that 16% of FY18 revenues are expressed in Israeli shekel, in addition to the entire equity income (we estimate a c €2.5m P&L contribution in FY18).

Exhibit 3: Financial summary

Year-end: December, €000s

 

 

2016

2017

2018e

2019e

2020e

INCOME STATEMENT

 

 

 

 

 

 

 

Total revenues

 

 

11,632

13,636

19,658

20,491

20,355

Cost of sales

 

 

(2,082)

(2,549)

(3,800)

(4,036)

(4,036)

Gross profit

 

 

9,550

11,087

15,858

16,455

16,319

SG&A (expenses)

 

 

(657)

(889)

(1,600)

(1,836)

(1,792)

R&D costs

 

 

0

0

0

0

0

Other income/(expense)

 

 

(2,111)

(2,721)

(2,300)

(1,900)

(1,900)

Depreciation and amortisation

 

 

(4,411)

(4,518)

(5,758)

(5,967)

(5,967)

Reported EBIT

 

 

2,371

2,959

6,200

6,752

6,661

Finance income/(expense)

 

 

(3,070)

(6,072)

(2,554)

(2,288)

(2,370)

Other income/(expense)

 

 

636

(3,156)

0

0

0

Reported PBT

 

 

(63)

(6,269)

3,646

4,464

4,291

Income tax expense (includes exceptionals)

 

 

(569)

(372)

(656)

(804)

(772)

Reported net income

 

 

(632)

(6,641)

2,990

3,661

3,519

Net income adjusted for minorities

(209)

(6,115)

2,490

3,049

2,930

Basic average number of shares, m

 

 

10,668

10,676

10,676

10,676

10,676

Basic EPS (€)

 

 

(0.02)

(0.57)

0.28

0.34

0.33

DPS (€)

 

 

0.00

0.00

0.09

0.11

0.12

Adjusted EBITDA

 

 

6,782

7,477

11,958

12,719

12,628

Adjusted EBIT

 

 

2,371

2,959

6,200

6,752

6,661

Adjusted PBT

 

 

(63)

(6,269)

3,646

4,464

4,291

Adjusted EPS

 

 

0.00

0.00

0.34

0.42

0.41

Adjusted diluted EPS

 

 

(0.02)

(0.57)

0.28

0.34

0.33

BALANCE SHEET

 

 

 

 

 

 

 

Property, plant and equipment

 

 

73,274

78,837

73,079

67,112

61,145

Goodwill

 

 

0

0

0

0

0

Intangible assets

 

 

0

5,505

5,505

5,505

5,505

Other non-current assets

 

 

37,096

67,517

66,667

66,817

66,967

Total non-current assets

 

 

110,370

151,859

145,251

139,434

133,617

Cash and equivalents

 

 

22,486

23,962

35,021

33,811

32,598

Inventories

 

 

0

0

0

0

0

Trade and other receivables

 

 

9,487

10,645

10,346

10,784

10,713

Other current assets

 

 

6,121

11,622

11,622

11,622

11,622

Total current assets

 

 

38,094

46,229

56,990

56,217

54,933

Non-current loans and borrowings

 

 

46,007

95,078

95,078

85,078

75,078

Other non-current liabilities

 

 

7,528

14,227

14,227

14,227

14,227

Total non-current liabilities

 

 

53,535

109,305

109,305

99,305

89,305

Trade and other payables

 

 

4,720

3,536

4,198

4,323

4,323

Current loans and borrowings

 

 

5,838

7,747

7,747

7,747

7,747

Other current liabilities

 

 

0

0

0

0

0

Total current liabilities

 

 

10,558

11,283

11,945

12,070

12,070

Equity attributable to company

 

 

85,072

78,641

81,631

84,305

86,616

Non-controlling interest

 

 

(701)

(1,141)

(641)

(29)

560

CASH FLOW STATEMENT

 

 

 

 

 

 

 

EBIT

 

 

2,371

2,959

6,200

6,752

6,661

Depreciation and amortisation

 

 

4,411

4,518

5,758

5,967

5,967

Share based payments

 

 

0

0

0

0

0

Other adjustments

 

 

3,274

(1,119)

500

612

588

Movements in working capital

 

 

76

(857)

961

(313)

71

Interest paid / received

 

 

(2,761)

(3,154)

(2,554)

(2,288)

(2,370)

Income taxes paid

 

 

(54)

(42)

(656)

(804)

(772)

Cash from operations (CFO)

 

 

7,317

2,305

10,209

9,926

10,145

Capex

 

 

(710)

(8,000)

(150)

(150)

(150)

Acquisitions & disposals net

 

 

(231)

(22,207)

0

0

0

Other investing activities

 

 

1,520

2,864

1,000

0

0

Cash used in investing activities (CFIA)

 

 

579

(27,343)

850

(150)

(150)

Net proceeds from issue of shares

 

 

(11)

(14)

0

0

0

Movements in debt

 

 

(317)

29,684

0

(10,000)

(10,000)

Dividends paid

 

 

(2,123)

0

0

(987)

(1,208)

Other financing activities

 

 

0

0

0

0

0

Cash from financing activities (CFF)

 

 

(2,451)

29,670

0

(10,987)

(11,208)

Currency translation differences and other

 

 

(153)

(3,156)

0

0

0

Increase/(decrease) in cash and equivalents

 

 

5,292

1,476

11,059

(1,210)

(1,213)

Cash and equivalents at end of period

 

 

22,486

23,962

35,021

33,811

32,598

Net (debt) cash

 

 

(32,375)

(80,391)

(69,332)

(60,542)

(51,755)

Movement in net (debt) cash over period

 

 

(2,283)

(48,016)

11,059

8,790

8,787

Source: Company data, Edison Investment Research


Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

EDISON ISRAEL DISCLAIMER

Disclosure regarding the scheme to enhance the awareness of investors to public companies in the technology and biomed sectors that are listed on the Tel Aviv Stock Exchange and participate in the scheme (hereinafter respectively “the Scheme”, “TASE”, “Participant” and/or “Participants”). Edison Investment Research (Israel) Ltd, the Israeli subsidiary of Edison Investment Research Ltd (hereinafter respectively “Edison Israel” and “Edison”), has entered into an agreement with the TASE for the purpose of providing research analysis (hereinafter “the Agreement”), regarding the Participants and according to the Scheme (hereinafter “the Analysis” or “Analyses”). The Analysis will be distributed and published on the TASE website (Maya), Israel Security Authority (hereinafter “the ISA”) website (Magna), and through various other distribution channels. The Analysis for each participant will be published at least four times a year, after publication of quarterly or annual financial reports, and shall be updated as necessary after publication of an immediate report with respect to the occurrence of a material event regarding a Participant. As set forth in the Agreement, Edison Israel is entitled to fees for providing its investment research services. The fees shall be paid by the Participants directly to the TASE, and TASE shall pay the fees directly to Edison. Subject to the terms and principals of the Agreement, the Annual fees that Edison Israel shall be entitled to for each Participant shall be in the range of $35,000-50,000. As set forth in the Agreement and subject to its terms, the Analyses shall include a description of the Participant and its business activities, which shall inter alia relate to matters such as: shareholders; management; products; relevant intellectual property; the business environment in which the Participant operates; the Participant's standing in such an environment including current and forecasted trends; a description of past and current financial positions of the Participant; and a forecast regarding future developments in and of such a position and any other matter which in the professional view of the Edison (as defined below) should be addressed in a research report (of the nature published) and which may affect the decision of a reasonable investor contemplating an investment in the Participant's securities. To the extent it is relevant, the Analysis shall include a schedule of scientific analysis of an expert in the field of life sciences. An "equity research abstract" shall accompany each Equity Research Report, describing the main points addressed. The full scope reports and reports where the investment case has materially changed will include a thorough analysis and discussion. Short update notes, where the investment case has not materially changed, will include a summary valuation discussion. The Agreement with TASE regarding the participation of Edison in the scheme for the research analysis of public companies does not and shall not constitute an approval or consent on the part of TASE or the ISA or any other exchange on which securities of the Company are listed, or any other securities’ regulatory authority which regulates the issuance of securities by the Company to the content of the Report or to the recommendation contained therein. A summary of this report is also published in the Hebrew language. In the event of any contradiction, inconsistency, discrepancy, ambiguity or variance between the English Report and the Hebrew summary of said Report, the English version shall prevail; and a note to this effect shall appear in any Hebrew summary of a Report. Edison is regulated by the Financial Conduct Authority. According to Article 12.3.2, Chapter 12 of the Conduct of Business Sourcebook, Edison, which produces or disseminates non-independent research, must ensure that it: 1) is clearly identified as a marketing communication; and 2) contains a clear and prominent statement that (or, in the case of an oral recommendation, to the effect that) it: a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and b) is not subject to any prohibition on dealing ahead of the dissemination of investment research. The financial promotion rules apply to non-independent research as though it were a marketing communication.

EDISON INVESTMENT RESEARCH DISCLAIMER
Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors.
This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2018. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Tel Aviv +44 (0)20 3734 1007
Medinat Hayehudim 60

Herzilya Pituach, 46766

Israel

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

295 Madison Avenue, 18th Floor

10017, New York

US

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Tel Aviv +44 (0)20 3734 1007
Medinat Hayehudim 60

Herzilya Pituach, 46766

Israel

ASLAN Pharmaceuticals — ASLAN004 a go for atopic dermatitis

ASLAN announced in July 2018 that it has received clinical trial authorisation in Singapore to conduct a Phase I study of ASLAN004 for the treatment of atopic dermatitis (AD). The product is a monoclonal antibody targeting interleukin 13 receptor α 1 (IL13Rα1). The Phase I dosing study will consist of a single dose escalation in healthy volunteers and a multiple dose escalation in AD patients.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free